Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 23 results.
User Information
Export Records
  1. 1.   Engineered Single Human CD4 Domains as Potent HIV-1 Inhibitors and Components of Vaccine Immunogens
  2. Chen, W. Z.; Feng, Y.; Gong, R.; Zhu, Z. Y.; Wang, Y. P.; Zhao, Q.; Dimitrov, D. S.
  3. Journal of Virology. 2011, Sep; 85(18): 9395-9405.
  1. 2.   Generation of HIV-1 primary isolates representative of plasma variants using the U87.CD4 cell line
  2. Heeregrave, E. J.; Ampofo, W. K.; Tetteh, J. K. A.; Ofori, M.; Ofori, S. B.; Shah, A. S.; Pollakis, G.; Paxton, W. A.
  3. Journal of Virological Methods. 2010, Nov; 169(2): 341-350.
  1. 3.   Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates
  2. Chen, W. Z.; Xiao, X. D.; Wang, Y. P.; Zhu, Z. Y.; Dimitrov, D. S.
  3. Antiviral Research. 2010, Oct; 88(1): 107-115.
  1. 4.   A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex
  2. Jacobs, A.; Quraishi, O.; Huang, X. C.; Bousquet-Gagnon, N.; Nault, G.; Francella, N.; Alvord, W. G.; Pham, N.; Soucy, C.; Robitaille, M.; Bridon, D.; Blumenthal, R.
  3. Journal of Biological Chemistry. 2007, Nov; 282(44): 32406-32413.
  1. 5.   Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques
  2. Kennedy, P. E.; Bera, T. K.; Wang, Q. C.; Gallo, M.; Wagner, W.; Lewis, M. G.; Berger, E. A.; Pastan, I.
  3. Journal of Leukocyte Biology. 2006, Nov; 80(5): 1175-1182.
  1. 6.   A mutation in the human immunodeficiency virus type 1 gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41
  2. Davis, M. R.; Jiang, J. Y.; Zhou, J.; Freed, E. O.; Aiken, C.
  3. Journal of Virology. 2006, Mar; 80(5): 2405-2417.
  1. 7.   Structure of a V3-containing HIV-1 gp120 core
  2. Huang, C. C.; Tang, M.; Zhang, M. Y.; Majeed, S.; Montabana, E.; Stanfield, R. L.; Dimitrov, D. S.; Korber, B.; Sodroski, J.; Wilson, I. A.; Wyatt, R.; Kwong, P. D.
  3. Science. 2005, NOV 11; 310(5750): 1025-1028.
  1. 8.   Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus
  2. Yuste, E.; Johnson, W.; Pavlakis, G. N.; Desrosiers, R. C.
  3. Journal of Virology. 2005, OCT; 79(19): 12455-12463.
  1. 9.   Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4
  2. Yang, Q. E.; Stephen, A. G.; Adelsberger, J. W.; Roberts, P. E.; Zhu, W. M.; Currens, M. J.; Feng, Y. X.; Crise, B. J.; Gorelick, R. J.; Rein, A. R.; Fisher, R. J.; Shoemaker, R. H.; Sei, S.
  3. Journal of Virology. 2005, MAY; 79(10): 6122-6133.
  1. 10.   TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells
  2. Herbeuval, J. P.; Boasso, A.; Grivel, J. C.; Hardy, A. W.; Anderson, S. A.; Dolan, M. J.; Chougnet, C.; Lifson, J. D.; Shearer, G. M.
  3. Blood. 2005 105(6): 2458-2464.
  1. 11.   Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades
  2. Zhang, M. Y.; Shu, Y.; Sidorov, I.; Dimitrov, D. S.
  3. Antiviral Research. 2004 61(3): 161-164.
  1. 12.   CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription
  2. Zhang, R.; Fichtenbaum, C. J.; Hildeman, D. A.; Lifson, J. D.; Chougnet, C.
  3. Journal of Immunology. 2004 172(4): 2678-2686.
  1. 13.   Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120
  2. Leavitt, M.; Park, E. J.; Sidorov, I. A.; Dimitrov, D. S.; Quinnan, G. V.
  3. Journal of Virology. 2003 77(1): 560-570.
  1. 14.   Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gpl120 is sterically restricted on primary human immunodeficiency virus type 1
  2. Labrijn, A. F.; Poignard, P.; Raja, A.; Zwick, M. B.; Delgado, K.; Franti, M.; Binley, J.; Vivona, V.; Grundner, C.; Huang, C. C.; Venturi, M.; Petropoulos, C. J.; Wrin, T.; Dimitrov, D. S.; Robinson, J.; Kwong, P. D.; Wyatt, R. T.; Sodroski, J.; Burton, D. R.
  3. Journal of Virology. 2003 77(19): 10557-10565.
  1. 15.   Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1
  2. Bouma, P.; Leavitt, M.; Zhang, P. F.; Sidorov, I. A.; Dimitrov, D. S.; Quinnan, G. V.
  3. Journal of Virology. 2003 77(14): 8061-8071.
  1. 16.   The HIV Env-mediated fusion reaction
  2. Gallo, S. A.; Finnegan, C. M.; Viard, M.; Raviv, Y.; Dimitrov, A.; Rawat, S. S.; Puri, A.; Durell, S.; Blumenthal, R.
  3. Biochimica Et Biophysica Acta-Biomembranes. 2003 1614(1): 36-50.
  1. 17.   Dendritic cell-mediated viral transfer to T cells is required for human immunodeficiency virus type 1 persistence in the face of rapid cell turnover
  2. Gummuluru, S.; KewalRamani, V. N.; Emerman, M.
  3. Journal of Virology. 2002 76(21): 10692-10701.
  1. 18.   Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus
  2. Chertova, E.; Bess, J. W.; Crise, B. J.; Sowder, R. C.; Schaden, T. M.; Hilburn, J. M.; Hoxie, J. A.; Benveniste, R. E.; Lifson, J. D.; Henderson, L. E.; Arthur, L. O.
  3. Journal of Virology. 2002 76(11): 5315-5325.
  1. 19.   Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes
  2. Moulard, M.; Phogat, S. K.; Shu, Y.; Labrijn, A. F.; Xiao, X. D.; Binley, J. M.; Zhang, M. Y.; Sidorov, I. A.; Broder, C. C.; Robinson, J.; Parren, P.; Burton, D. R.; Dimitrov, D. S.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2002 99(10): 6913-6918.
  1. 20.   The Hiv-Inactivating Protein, Cyanovirin-N, Does Not Block Gp120-Mediated Virus-to-Cell Binding
  2. Mariner, J. M.; McMahon, J. B.; Okeefe, B. R.; Nagashima, K.; Boyd, M. R.
  3. Biochemical and Biophysical Research Communications. 1998 248(3): 841-845.
  1. 21.   Increase of Primary Hiv-1 Production in Human Peripheral Blood Mononuclear Cells By Intermittent Medium Replenishment
  2. Wu, S. C.; Spouge, J. L.; Nara, P. L.
  3. Biotechnology Progress. 1998 14(3): 540-542.
  1. 22.   Analysis of Sequence Requirements For Biological Activity of Cyanovirin-N, a Potent Hiv (Human Immunodeficiency Virus)-Inactivating Protein
  2. Mori, T.; Shoemaker, R. H.; Gulakowski, R. J.; Krepps, B. L.; McMahon, J. B.; Gustafson, K. R.; Pannell, L. K.; Boyd, M. R.
  3. Biochemical and Biophysical Research Communications. 1997 238(1): 218-222.
  1. 23.   Construction and Enhanced Cytotoxicity of a
  2. Mori, T.; Shoemaker, R. H.; McMahon, J. B.; Gulakowski, R. J.; Gustafson, K. R.; Boyd, M. R.
  3. Biochemical and Biophysical Research Communications. 1997 239(3): 884-888.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel